BCI
BMRN icon

Brinker Capital Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Brinker Capital Investments’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7M Buy
29,779
+18,297
+159% +$1M 0.01% 886
2026
Q1 		$649K Buy
11,482
+3,830
+50% +$223K 0.01% 1349
2025
Q4 		$455K Buy
+7,652
New +$417K ﹤0.01% 1628
2024
Q3 		– Sell
-13,083
Closed -$1.08M – 1787
2024
Q2 		$1.08M Sell
13,083
-6,534
-33% -$544K 0.01% 957
2024
Q1 		$1.71M Sell
19,617
-568
-3% -$50.8K 0.02% 732
2023
Q4 		$2M Sell
20,185
-2,150
-10% -$190K 0.02% 630
2023
Q3 		$1.98M Buy
22,335
+3,785
+20% +$337K 0.02% 614
2023
Q2 		$1.61M Sell
18,550
-1,029
-5% -$96.8K 0.02% 748
2023
Q1 		$1.9M Buy
19,579
+438
+2% +$45.4K 0.02% 615
2022
Q4 		$1.98M Sell
19,141
-1,883
-9% -$177K 0.04% 486
2022
Q3 		$1.78M Buy
21,024
+56
+0.3% +$4.99K 0.04% 499
2022
Q2 		$1.74M Buy
20,968
+4,424
+27% +$352K 0.03% 529
2022
Q1 		$1.28M Buy
16,544
+4,797
+41% +$401K 0.02% 705
2021
Q4 		$1.04M Sell
11,747
-14,626
-55% -$1.21M 0.02% 808
2021
Q3 		$2.2M Hold
26,373
– – 0.03% 524
2021
Q2 		$2.2M Buy
26,373
+4,521
+21% +$358K 0.03% 577
2021
Q1 		$1.65M Sell
21,852
-21,934
-50% -$1.79M 0.02% 566
2020
Q4 		$3.84M Buy
43,786
+25,097
+134% +$1.99M 0.06% 394
2020
Q3 		$1.42M Buy
+18,689
New +$1.89M 0.02% 582
2019
Q4 		– Sell
-77
Closed -$5K – 806
2019
Q3 		$5K Buy
+77
New +$5.93K ﹤0.01% 628

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Brinker Capital Investments's BMRN Position: Q2 2026 in Review

Brinker Capital Investments increased its BioMarin Pharmaceuticals (BMRN) stake by 159% in Q2 2026, buying an estimated $1M and bringing the position to 29,779 shares worth $1.7M. The position accounts for 0.01% of the portfolio, ranked #886.

Brinker Capital Investments first reported a position in BMRN in Q3 2019 and has held it in 20 quarters since. The position peaked at $3.84M in Q4 2020. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Brinker Capital Investments held 29,779 shares of BioMarin Pharmaceuticals worth $1.7M as of Q2 2026.
  • Brinker Capital Investments bought 18,297 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1M.
  • BioMarin Pharmaceuticals made up 0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #886 holding.
  • Brinker Capital Investments first reported a position in BioMarin Pharmaceuticals in Q3 2019 and has held it in 20 quarters since.
  • Brinker Capital Investments's BioMarin Pharmaceuticals position peaked at $3.84M in Q4 2020.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.